Skip to search formSkip to main content

L 743,872

Known as: L 743872, L-743,872, L-743872 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CaspofunginCaspofungin acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum, Aspergillus… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1998
1998
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.
In addition to its potent efficacy in animal models against Candida sp., Aspergillus fumigatus, and Histoplasma capsulatum, the… Expand
Is this relevant?
1998
1998
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
MK-0991 (formerly L-743,872) is a water soluble semisynthetic echinocandin that possess potent, broad-spectrum antifungal… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
The echinocandin MK-0991, formerly L-743,872, is a water-soluble lipopeptide that has been demonstrated in preclinical studies to… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
MK-0991 (L-743,872) is a potent antifungal agent featuring long half-life pharmacokinetics. The pharmacokinetics of MK-0991… Expand
  • figure 1
  • table 2
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
The in vivo activity of the Merck antifungal echinocandin drug candidate MK-0991 (L-743,872) was evaluated in mouse models of… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the… Expand
Is this relevant?
1997
1997
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Cryptococcus neoformans infections in patients with AIDS are often incurable, despite aggressive antifungal therapy. Combination… Expand
Is this relevant?
1997
1997
In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.
L-733,560 and L-743,872 are water-soluble pneumocandins with potent antifungal activity. By beginning with the NCCLS M27-T method… Expand
Is this relevant?
1997
1997
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.
L-743,872 is a broad-spectrum pneumocandin antifungal drug developed by Merck Research Co., and in the present work it was… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE